STOK
Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$29.81
−0.60%Aug 20, 2026, 07:24 UTC
Bank of America Corp DE increased its stake in Stoke Therapeutics, Inc. by 163.4% during the first quarter, buying an additional 336,931 shares, according to a recent SEC filing.
Source:Aug 3, 2026, 22:04 UTC
Stoke Therapeutics announced that its Phase III EMPEROR study of zorevunersen in Dravet syndrome patients remains on track for a data readout in Q3 2027, following completion of enrollment ahead of the planned rolling NDA submission.
Aug 3, 2026, 20:01 UTC
Stoke Therapeutics reported its financial results for the second quarter ended June 30, 2026, and provided business updates including progress of its global Phase program for zorevunersen in Dravet syndrome.
Jun 30, 2026, 12:00 UTC
Stoke Therapeutics completed enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome.
Source: